Procaps Group and BDR sign agreement for oncology molecules
Procaps Group has signed an agreement with BDR for 27 oncology molecules for Latin America, including 20 Tirosyne Kinase Inhibitors (TKIs).
Stay updated with breaking news from Camilo Camacho. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Procaps Group has signed an agreement with BDR for 27 oncology molecules for Latin America, including 20 Tirosyne Kinase Inhibitors (TKIs).
The Agreement Substantially Increases Procaps' Participation in the Oncology Market in the LatAm Region ...
Introduces New High Temperature Gummy Technology Platform that Solves Formulation and Distribution Challenges ... -Today at 08:33 am- MarketScreener
Press release content from Business Wire. The AP news staff was not involved in its creation.
Con el símbolo "PROC" y "PROCW" se cotizarán las acciones ordinarias y warrants. | Economía | Portafolio.co